The preference for SGLT2 inhibitor use in type 2 diabetes with congestive heart failure is based on extensive clinical data from the DAPA-HF, EMPEROR, DELIVER, and other trials demonstrating reduced mortality and hospitalizations in heart failure with either reduced or preserved ejection fraction (reviewed in18). The gene discussed is SLC5A2; the disease is hydrops fetalis.